| Nina Frank, DO | |
|
6245 Inkster Rd, Garden City, MI 48135-4001 | |
| (734) 421-3300 | |
| Not Available |
| Full Name | Nina Frank |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 13 Years |
| Location | 6245 Inkster Rd, Garden City, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215215736 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 5101019511 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Newberg Medical Center | Newberg, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Oregon | 0648183608 | 1328 |
News Archive
Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.
HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope and Serbia operating subsidiary Slavica Bio Chem are providing this news release to bring attention to today's Pink Sheets filing,
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC) Cetirizine Cherry Syrup, 1mg/ml. Shipments will begin in the Company's fiscal first quarter 2011. Cherry joins the currently available grape flavor cetirizine syrup in Perrigo's product portfolio, giving patients a choice of store brand flavors.
The University of Manchester study found that wearers who failed to remove their lenses before bedtime had an increased risk of developing keratitis than those who routinely took out their lenses before going to sleep.
› Verified 7 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023488343 PECOS PAC ID: 0648183608 Enrollment ID: O20031106000652 |
News Archive
Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.
HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope and Serbia operating subsidiary Slavica Bio Chem are providing this news release to bring attention to today's Pink Sheets filing,
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC) Cetirizine Cherry Syrup, 1mg/ml. Shipments will begin in the Company's fiscal first quarter 2011. Cherry joins the currently available grape flavor cetirizine syrup in Perrigo's product portfolio, giving patients a choice of store brand flavors.
The University of Manchester study found that wearers who failed to remove their lenses before bedtime had an increased risk of developing keratitis than those who routinely took out their lenses before going to sleep.
› Verified 7 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114015971 PECOS PAC ID: 9335057447 Enrollment ID: O20031117000153 |
News Archive
Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.
HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope and Serbia operating subsidiary Slavica Bio Chem are providing this news release to bring attention to today's Pink Sheets filing,
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC) Cetirizine Cherry Syrup, 1mg/ml. Shipments will begin in the Company's fiscal first quarter 2011. Cherry joins the currently available grape flavor cetirizine syrup in Perrigo's product portfolio, giving patients a choice of store brand flavors.
The University of Manchester study found that wearers who failed to remove their lenses before bedtime had an increased risk of developing keratitis than those who routinely took out their lenses before going to sleep.
› Verified 7 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952482275 PECOS PAC ID: 3072415652 Enrollment ID: O20040123000519 |
News Archive
Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.
HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope and Serbia operating subsidiary Slavica Bio Chem are providing this news release to bring attention to today's Pink Sheets filing,
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC) Cetirizine Cherry Syrup, 1mg/ml. Shipments will begin in the Company's fiscal first quarter 2011. Cherry joins the currently available grape flavor cetirizine syrup in Perrigo's product portfolio, giving patients a choice of store brand flavors.
The University of Manchester study found that wearers who failed to remove their lenses before bedtime had an increased risk of developing keratitis than those who routinely took out their lenses before going to sleep.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nina Frank, DO 6245 Inkster Rd, Garden City, MI 48135-4001 Ph: (734) 421-3300 | Nina Frank, DO 6245 Inkster Rd, Garden City, MI 48135-4001 Ph: (734) 421-3300 |
News Archive
Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.
HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope and Serbia operating subsidiary Slavica Bio Chem are providing this news release to bring attention to today's Pink Sheets filing,
Perrigo Company today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC) Cetirizine Cherry Syrup, 1mg/ml. Shipments will begin in the Company's fiscal first quarter 2011. Cherry joins the currently available grape flavor cetirizine syrup in Perrigo's product portfolio, giving patients a choice of store brand flavors.
The University of Manchester study found that wearers who failed to remove their lenses before bedtime had an increased risk of developing keratitis than those who routinely took out their lenses before going to sleep.
› Verified 7 days ago
Brittany Harrington, D.O. General Practice Medicare: Accepting Medicare Assignments Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-4486 | |
Mahmudur Rahman, DO, MS General Practice Medicare: Accepting Medicare Assignments Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-4486 | |
Aline Victoire Lowah Kuate, NP General Practice Medicare: Accepting Medicare Assignments Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-3300 | |
Christopher Hyungjin Yun, DO General Practice Medicare: Medicare Enrolled Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-4486 | |
Sarah S Jacob, MD General Practice Medicare: Accepting Medicare Assignments Practice Location: 2020 Middlebelt Rd, Garden City Medical Center Pc, Garden City, MI 48135 Phone: 734-522-3770 Fax: 734-522-6114 | |
Kashif Khan, MD General Practice Medicare: Medicare Enrolled Practice Location: 6245 Inkster Rd, Garden City, MI 48135 Phone: 734-458-4486 Fax: 734-458-4496 |